- Home
- PLBC vs PBYI Comparison
PLBC vs PBYI Comparison
Compare PLBC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBC | PBYI |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 263.4M |
| IPO Year | 2002 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PLBC | PBYI |
|---|---|---|
| Price | $47.54 | $6.14 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $55.50 | N/A |
| AVG Volume (30 Days) | 34.6K | ★ 432.9K |
| Earning Date | 04-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.54 | 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $16.24 | ★ $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.71 | $2.58 |
| 52 Week High | $54.58 | $7.68 |
Technical Indicators
Market Signals| Indicator | PLBC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 45.73 |
| Support Level | $40.95 | $5.85 |
| Resistance Level | $49.24 | $6.15 |
| Average True Range (ATR) | 1.29 | 0.23 |
| MACD | -0.35 | -0.01 |
| Stochastic Oscillator | 17.40 | 29.38 |
Price Performance
Historical ComparisonAbout PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.